UnitedHealth Group saw revenue climb 13.3% in the first quarter of 2018 over the prior-year period. What does Q2 have in store?
News briefs for the week of May 6.
Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.
Healthcare giant Johnson & Johnson plans next month to disclose price increases of its prescription drugs as the industry tries to calm the storm over soaring prices.
Johnson & Johnson says it is paying more than $4.33 billion in cash to buy the eye health unit of Abbott Laboratories to boost its vision business.
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
Five years ago, medical-device maker Ethicon acquired Sterilmed, a company that reprocesses and remanufactures medical devices. The combination helped Ethicon executives recognize the cost-efficiency and environmental benefits that could come from better reprocessing services and more collaboration...
While the latest cancer drugs emerging from drug and biotechnology company labs can come with hefty price tags, they don't necessarily have a lot of evidence showing they actually work.
Joe Kiani, founder of Masimo Corp., has vaulted to the top of the list of healthcare's highest paid executives through an unusual golden parachute built into his stock option plan. Special deals and special circumstances dominated this year's list of top-paid CEOs in Modern Healthcare's analysis.
The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.